Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma.
Changhui LiBo ZhangJindong GuoFang HuWei NieXiaoxuan ZhengLixin WangYuqing LouYinchen ShenBaohui HanXueyan ZhangPublished in: Targeted oncology (2020)
In this retrospective analysis, EGFR-TKIs combined with chemotherapy could improve PFS. Further, the combined treatment could delay BM occurrence and decrease the incidence of BM as initial progression.